Фармакоэкономические аспекты длительного лечения палиперидоном пальмитатом больных с первым эпизодом шизофрении

Любов Евгений Борисович, Фролов Максим Юрьевич, Чапурин Сергей Анатольевич et al. · Социальная и клиническая психиатрия · 2014

Methods: A Markov decision analytic model was developed to evaluate the cost effectiveness of paliperidone palmitate (PP) as maintenance treatment vs. routine (i.e., typical) treatment (ТТ) for two cohorts of multi-episode (two or more relapses) patients with recently diagnosed schizophrenia from the perspective of the Russia healthcare system. Treatment efficacy from clinical trial data has been adjusted in the model based on level of compliance to reflect real-world effectiveness. All direct medical costs of the management of schizophrenia are included. In addition, given the high societal burden of schizophrenia, indirect costs including unemployment and productivity had be evaluated. Probability of relapse, level of adherence, side-effects (i.e., extrapyramidal symptoms) and treatment switch were derived from long-term observational data when feasible. In the model, the patients may be in a relapse state or in a stable state. Outcomes will be generated for the duration in each health state. Incremental cost-effectiveness outcomes, discounted at 7,4% annually, included cost per additional remission day and cost per relapse avoided (expressed in 2013 Rubl.). Results: the long-term PP is cost saving (economically dominant): more effective (less relapses) treatment option compared with ТТ over a 5-year time horizon but results in higher costs in base-case scenario from a Russian medical but not societal perspective. The result is very sensitive to cost PP.

Cited by 0 works.

Authors